相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cyclooxygenase-1, not cyclooxygenase-2, is responsible for physiological production of prostacyclin in the cardiovascular system
Nicholas S. Kirkby et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial
Francis K. L. Chan et al.
LANCET (2010)
Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis
Matthew C. Becker et al.
AMERICAN HEART JOURNAL (2009)
Differential Effects of Selective Cyclooxygenase-2 Inhibitors on Vascular Smooth Muscle Ion Channels May Account for Differences in Cardiovascular Risk Profiles
Lioubov I. Brueggemann et al.
MOLECULAR PHARMACOLOGY (2009)
Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial (The MEDAL study)
Bernard Combe et al.
RHEUMATOLOGY (2009)
A randomized, multicentre, double-blind, parallel-group study to assess the adverse event-related discontinuation rate with celecoxib and diclofenac in elderly patients with osteoarthritis
L. E. Dahlberg et al.
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY (2009)
Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials - The cross trial safety analysis
Scott D. Solomon et al.
CIRCULATION (2008)
Clinical Pharmacokinetic and Pharmacodynamic Profile of Etoricoxib
Jody K. Takemoto et al.
CLINICAL PHARMACOKINETICS (2008)
Cyclooxygenase and prostaglandin synthases in atherosclerosis: Recent insights and future perspectives
Francesco Cipollone et al.
PHARMACOLOGY & THERAPEUTICS (2008)
Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II)
K. Krueger et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies
C. O. Bingham et al.
RHEUMATOLOGY (2007)
Risk of cardiovascular events in patients receiving celecoxib: A meta-analysis of randomized clinical trials
William B. White et al.
AMERICAN JOURNAL OF CARDIOLOGY (2007)
Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison
Christopher P. Cannon et al.
LANCET (2006)
Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials
Patricia M. Kearney et al.
BMJ-BRITISH MEDICAL JOURNAL (2006)
COX-2 inhibitors and the heart: are all coxibs the same?
P Sooriakumaran
POSTGRADUATE MEDICAL JOURNAL (2006)
Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I study
G Singh et al.
AMERICAN JOURNAL OF MEDICINE (2006)
Non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction
S Hernández-Díaz et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2006)
Comparison of the COX-inhibiting nitric oxide donator AZD3582 and rofecoxib in treating the signs and symptoms of osteoarthritis of the knee
TJ Schnitzer et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2005)
Evaluation of the comparative efficacy of etoricoxib and ibuprofen for treatment of patients with osteoarthritis: A randomized, double-blind, placebo-controlled trial
CW Wiesenhutter et al.
MAYO CLINIC PROCEEDINGS (2005)
Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery
NA Nussmeier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
The effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus
JR Sowers et al.
ARCHIVES OF INTERNAL MEDICINE (2005)
Acute congestive heart failure induced by rofecoxib
RJ Campbell et al.
JOURNAL OF THE AMERICAN BOARD OF FAMILY PRACTICE (2004)
Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial
ME Farkouh et al.
LANCET (2004)
Risk of cardiovascular events and rofecoxib: cumulative meta-analysis
P Juni et al.
LANCET (2004)
Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification: comparison to sulfonamide COX-2 inhibitors and NSAIDs
MF Walter et al.
ATHEROSCLEROSIS (2004)
Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study
M Mamdani et al.
LANCET (2004)
Pharmacokinetics and metabolism of lumiracoxib in healthy male subjects
JB Mangold et al.
DRUG METABOLISM AND DISPOSITION (2004)
Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis - A randomized, controlled trial
JR Lisse et al.
ANNALS OF INTERNAL MEDICINE (2003)
Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery
E Ott et al.
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY (2003)
Heart failure in the elderly
N Yamasaki et al.
INTERNAL MEDICINE (2003)
Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses
F Song et al.
BMJ-BRITISH MEDICAL JOURNAL (2003)
A comparison of the therapeutic efficacy and tolerability of etoricoxib and diclofenac in patients with osteoarthritis
J Zacher et al.
CURRENT MEDICAL RESEARCH AND OPINION (2003)
A placebo and active comparator-controlled trial of rofecoxib for the treatment of rheumatoid arthritis
PP Geusens et al.
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY (2002)
Drug therapy: The coxibs, selective inhibitors of cyclooxygenase-2.
GA FitzGerald et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomised controlled trials
M Pahor et al.
LANCET (2000)
Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis.
C Bombardier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Rofecoxib, a new cyclooxygenase 2 inhibitor, shows sustained efficacy, comparable with other nonsteroidal anti-inflammatory drugs -: A 6-week and a 1-year trial in patients with osteoarthritis
K Saag et al.
ARCHIVES OF FAMILY MEDICINE (2000)
分享论文
